Guest: Efrat Dotan, MD

Guest: Shubham Pant, MD, MBBS

Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens.

This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups.

Complete both modules, answer pre- and post-test questions and start earning CME credits.

This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment